Process optimization of hot-melt extruded filaments for FDM 3D printing of personalized low-dose fludrocortisone acetate oral dosage forms.

Bourcy, Quentin; Jennotte, Olivier; Evrard, Brigitte; Lechanteur, Anna

doi:10.1016/j.ijpharm.2026.126865

Article (Scientific journals)

Process optimization of hot-melt extruded filaments for FDM 3D printing of personalized low-dose fludrocortisone acetate oral dosage forms.

Bourcy, Quentin; Jennotte, Olivier; Evrard, Brigitte et al.

2026 • In International Journal of Pharmaceutics, 697, p. 126865

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/347984

DOI
10.1016/j.ijpharm.2026.126865

PubMed
41966428

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

1-s2.0-S0378517326003133-main_Aut-V.pdf

Author postprint (1.63 MB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

3D-printing; Additive manufacturing; Fludrocortisone acetate; Fused filament fabrication; Hot-melt extrusion; Low-dosage oral forms; Personalized medicine

Abstract :

[en] Low-dose oral formulations are often associated with poor dose accuracy (mass and content non-uniformity) and limited reproducibility. Three-dimensional printing (3DP), particularly Fused Deposition Modeling (FDM), has emerged as a promising strategy to overcome limitations of conventional pharmaceutical compounding for oral therapies. FDM enables precise, digitally controlled deposition for decentralized, on-demand manufacturing at the Point of Care (PoC), but its implementation is limited by the availability of suitable pharmaceutical filaments. Especially at sub-percent drug loadings, achieving homogeneous drug distribution at such low concentrations is a major challenge. Fludrocortisone Acetate (FCA), a micronized corticosteroid administered at microgram daily doses and commonly compounded in Belgium in the absence of authorized products, was selected as a model drug. This study aimed to develop homogeneous low-dose (0.5% w/w) FCA-loaded filaments by Hot-Melt Extrusion (HME) suitable for FDM printing. The effects of adding 1% of a flow regulator (Aerosil® 200) and screw configuration (one vs. two kneading zones) on extrusion process parameters and drug distribution were investigated. Aerosil® 200 improved powder flow and feeding stability, and filament homogeneity resulted from the combined effect of formulation and screw configuration. Optimized filaments showed suitable mechanical properties for FDM and enabled printing of Immediate-Release (IR) oral dosage forms containing 50, 100, and 200 µg FCA. Printed waffle-shaped units complied with European Pharmacopoeia requirements for mass and content uniformity, hardness, and friability. Dissolution confirmed an IR profile, with > 80% FCA released within 45 min. This work demonstrates the feasibility of manufacturing pharmaceutically compliant low-dose dosage forms by combining HME and FDM, offering a reliable alternative to conventional compounding and advancing point-of-care personalized medicine.

Research Center/Unit :

CIRM - Centre Interdisciplinaire de Recherche sur le Médicament - ULiège

Disciplines :

Pharmacy, pharmacology & toxicology

Author, co-author :

Bourcy, Quentin ; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique

Jennotte, Olivier ; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique

Evrard, Brigitte ; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique

Lechanteur, Anna ; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique

Language :

English

Title :

Process optimization of hot-melt extruded filaments for FDM 3D printing of personalized low-dose fludrocortisone acetate oral dosage forms.

Publication date :

09 April 2026

Journal title :

International Journal of Pharmaceutics

ISSN :

0378-5173

eISSN :

1873-3476

Publisher :

Elsevier BV, Netherlands

Volume :

697

Pages :

126865

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://api.elsevier.com/content/article/PII:S0378517326003133?httpAccept=text/xml

Funders :

Walloon Region

Available on ORBi :

since 18 August 2026

Statistics

Number of views

61 (26 by ULiège)

Number of downloads

26 (7 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Ahmed, A.A., Schimmel, K.J.M., Tubic-Grozdanis, M., Tuleu, C., Smith, J., Soulairol, I., Dadkhah, A., Paulson, M., Lechanteur, A., Carrez, L., Schnor, T., Lagarce, F., Le Brun, P.P.H., Crauste-Manciet, S., Expert opinion on extrusion-based pharmaceutical 3D printing from the european society of hospital pharmaceutical technology (GERPAC). International Journal of Pharmaceutics, 2025, Elsevier B.V., 10.1016/j.ijpharm.2025.126321.
Aho, J., Bøtker, J.P., Genina, N., Edinger, M., Arnfast, L., Rantanen, J., Roadmap to 3D-printed oral pharmaceutical dosage forms: feedstock filament properties and characterization for fused deposition modeling. J. Pharm. Sci. 108:1 (2019), 26–35, 10.1016/j.xphs.2018.11.012 Elsevier B.V.
Alhnan, M.A., Okwuosa, T.C., Sadia, M., Wan, K.W., Ahmed, W., Arafat, B., Emergence of 3D printed dosage forms: opportunities and challenges. Pharm. Res. 33:8 (2016), 1817–1832, 10.1007/s11095-016-1933-1 Springer New York LLC.
Association Pharmaceutique Belge. (2021). Résultats du cycle d'analyse Gélules à 0,1 mg de fludrocortisone acétate. https://www.apb.be/nl/my/Magistrale-bereidingen/Pages/default.aspx.
Auer, M.K., Nordenström, A., Lajic, S., Reisch, N., Congenital adrenal hyperplasia. Lancet Vol. 401:10372 (2023), 227–244, 10.1016/S0140-6736(22)01330-7 Elsevier B.V.
Bandari, S., Nyavanandi, D., Dumpa, N., Repka, M.A., Coupling hot melt extrusion and fused deposition modeling: critical properties for successful performance. Adv. Drug Deliv. Rev. 172 (2021), 52–63, 10.1016/j.addr.2021.02.006 Elsevier B.V.
Beitler, B.G., Abraham, P.F., Glennon, A.R., Tommasini, S.M., Lattanza, L.L., Morris, J.M., Wiznia, D.H., Interpretation of regulatory factors for 3D printing at hospitals and medical centers, or at the point of care. 3D Print. Med., 8(1), 2022, 10.1186/s41205-022-00134-y BioMed Central Ltd.
Bornstein, S.R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G.D., Husebye, E.S., Merke, D.P., Murad, M.H., Stratakis, C.A., Torpy, D.J., Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101:2 (2016), 364–389, 10.1210/jc.2015-1710.
Ceccato, F., Torchio, M., Tizianel, I., Peleg Falb, M., Barbot, M., Sabbadin, C., Betterle, C., Scaroni, C., Renin and electrolytes indicate the mineralocorticoid activity of fludrocortisone: a 6 year study in primary adrenal insufficiency. J. Endocrinol. Invest. 46:1 (2023), 111–122, 10.1007/s40618-022-01889-1.
Chamberlain, R., Windolf, H., Geissler, S., Quodbach, J., Breitkreutz, J., Precise dosing of pramipexole for low-dosed filament production by hot melt extrusion applying various feeding methods. Pharmaceutics, 14(1), 2022, 10.3390/pharmaceutics14010216.
Colombo, P., Bettini, R., Peppas, N.A., Observation of swelling process and diffusion front position during swelling in hydroxypropyl methyl cellulose (HPMC) matrices containing a soluble drug. J. Control. Release, 61, 1999.
Curti, C., Brandin, T., Kabac, T., Gallice, S., Martin-Privat, D., Lamy, E., Vanelle, P., Quality control of magistral preparation in community pharmacies: regulatory requirements and suggested improvement. Pharmacien Hospitalier et Clinicien 55:3 (2020), 268–274, 10.1016/j.phclin.2020.04.009.
Daminabo, S.C., Goel, S., Grammatikos, S.A., Nezhad, H.Y., Thakur, V.K., Fused deposition modeling-based additive manufacturing (3D printing): techniques for polymer material systems. Mater. Today Chem., 16, 2020, 10.1016/j.mtchem.2020.100248 Elsevier Ltd.
D'Hondt, M., Wynendaele, E., Vandercruyssen, K., Bauters, T., Vandenbroucke, J., Mullens, S., Vervaet, C., Remon, J.P., De Spiegeleer, B., Investigation of active pharmaceutical ingredient loss in pharmaceutical compounding of capsules. J. Pharm. Biomed. Anal. 96 (2014), 68–76, 10.1016/j.jpba.2014.03.020.
Domsta, V., Boralewski, T., Ulbricht, M., Schick, P., Krause, J., Seidlitz, A., Stability of dexamethasone during hot-melt extrusion of filaments based on Eudragit® RS, ethyl cellulose and polyethylene oxide. International Journal of Pharmaceutics: X, 8, 2024, 10.1016/j.ijpx.2024.100263.
Dooms, M., Carvalho, M., Compounded medication for patients with rare diseases. Orphanet J. Rare Dis., 13(1), 2018, 10.1186/s13023-017-0741-y.
Formulaire Thérapeutique, Magistrale., Bruxelles : Agence Fédérale des Médicaments et des Produits de, 2016, Santé (AFMPS),3ième édition.
Gioumouxouzis, C.I., Karavasili, C., Fatouros, D.G., Recent advances in pharmaceutical dosage forms and devices using additive manufacturing technologies. Drug Discov. Today 24:2 (2019), 636–643, 10.1016/j.drudis.2018.11.019 Elsevier Ltd.
Goyanes, A., Chang, H., Sedough, D., Hatton, G.B., Wang, J., Buanz, A., Gaisford, S., Basit, A.W., Fabrication of controlled-release budesonide tablets via desktop (FDM) 3D printing. Int. J. Pharm. 496:2 (2015), 414–420, 10.1016/j.ijpharm.2015.10.039.
Goyanes, A., Scarpa, M., Kamlow, M., Gaisford, S., Basit, A.W., Orlu, M., Patient acceptability of 3D printed medicines. Int. J. Pharm. 530:1–2 (2017), 71–78, 10.1016/j.ijpharm.2017.07.064.
Haute Autorité de Santé. (2025). Fludrocortisone. https://www.has-sante.fr/jcms/fc_2875171/fr/resultat-de-recherche?text=fludrocortisone&tmpParam=&opSearch=&types=technologies&FACET_SUB_ACTIVE=fludrocortisone.
Ilyés, K., Kovács, N.K., Balogh, A., Borbás, E., Farkas, B., Casian, T., Marosi, G., Tomuță, I., Nagy, Z.K., The applicability of pharmaceutical polymeric blends for the fused deposition modelling (FDM) 3D technique: material considerations–printability–process modulation, with consecutive effects on in vitro release, stability and degradation. Eur. J. Pharm. Sci. 129 (2019), 110–123, 10.1016/j.ejps.2018.12.019.
Jamróz, W., Szafraniec, J., Kurek, M., Jachowicz, R., 3D printing in pharmaceutical and medical applications – Recent achievements and challenges. Pharm. Res., 35(9), 2018, 10.1007/s11095-018-2454-x.
Jennotte, O., Koch, N., Lechanteur, A., Evrard, B., Three-dimensional printing technology as a promising tool in bioavailability enhancement of poorly water-soluble molecules: a review. Int. J. Pharm., 580, 2020, 10.1016/j.ijpharm.2020.119200.
Jennotte, O., Koch, N., Lechanteur, A., Evrard, B., Development of amorphous solid dispersions of cannabidiol: influence of the carrier, the hot-melt extrusion parameters and the use of a crystallization inhibitor. J. Drug Delivery Sci. Technol., 71, 2022, 10.1016/j.jddst.2022.103372.
Jennotte, O., Koch, N., Lechanteur, A., Evrard, B., Formulation and quality consideration of cannabidiol printed forms produced by fused-deposition modeling. J. Drug Delivery Sci. Technol., 87, 2023, 10.1016/j.jddst.2023.104837.
Karalia, D., Siamidi, A., Karalis, V., Vlachou, M., 3d‐printed oral dosage forms: mechanical properties, computational approaches and applications. Pharmaceutics, Vol. 13(9), 2021, 10.3390/pharmaceutics13091401 MDPI.
Khaled, S.A., Burley, J.C., Alexander, M.R., Yang, J., Roberts, C.J., 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. J. Control. Release 217 (2015), 308–314, 10.1016/j.jconrel.2015.09.028.
Korte, C., Quodbach, J., Formulation development and process analysis of drug-loaded filaments manufactured via hot-melt extrusion for 3D-printing of medicines. Pharm. Dev. Technol. 23:10 (2018), 1117–1127, 10.1080/10837450.2018.1433208.
Kreft, K., Lavrič, Z., Gradišar Centa, U., Mihelčič, M., Slemenik Perše, L., Dreu, R., Correlating mechanical and rheological filament properties to processability and quality of 3D printed tablets using multiple linear regression. Int. J. Pharm., 651, 2024, 10.1016/j.ijpharm.2023.123719.
Lang, B., McGinity, J.W., Williams, R.O., Hot-melt extrusion-basic principles and pharmaceutical applications. Drug Dev. Ind. Pharm. Vol. 40:9 (2014), 1133–1155, 10.3109/03639045.2013.838577 Informa Healthcare.
Macedo, J., da Costa, N.F., Vanhoorne, V., Vervaet, C., Pinto, J.F., The precision and accuracy of 3D printing of tablets by fused deposition modelling. J. Pharm. Sci. 111:10 (2022), 2814–2826, 10.1016/j.xphs.2022.05.006.
Majerová, D., Kulaviak, L., Růžička, M., Štěpánek, F., Zámostný, P., Effect of colloidal silica on rheological properties of common pharmaceutical excipients. Eur. J. Pharm. Biopharm. 106 (2016), 2–8, 10.1016/j.ejpb.2016.04.025.
Mathaut, S., Bordenave, J., Fratta, A., Benoit, G., Quality control of hospital preparations: results concerning capsules production in a child hospital. Ann. Pharm. Fr. 64:1 (2006), 44–51, 10.1016/s0003-4509(06)75293-2 Elsevier Masson SAS.
Mohapatra, S., Kar, R.K., Biswal, P.K., Bindhani, S., Approaches of 3D printing in current drug delivery. Sensors International, 3, 2022, KeAi Communications Co, 10.1016/j.sintl.2021.100146.
Nascimento, G.M., Cardoso, P.H.N., da Silva, E.M.E., Tavares, G.F., Olivier, N.C., Faia, P.M., Araújo, E.S., Silva, F.S., FDM 3D printing filaments with pH-dependent solubility: preparation, characterization and in vitro release kinetics. Processes, 12(12), 2024, 10.3390/pr12122916.
Neumann, U., Burau, D., Spielmann, S., Whitaker, M.J., Ross, R.J., Kloft, C., Blankenstein, O., Quality of compounded hydrocortisone capsules used in the treatment of children. Eur. J. Endocrinol. 177:2 (2017), 239–242, 10.1530/EJE-17-0248.
Norman, J., Madurawe, R.D., Moore, C.M.V., Khan, M.A., Khairuzzaman, A., A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Advanced Drug Delivery Reviews, 108, 2017, Elsevier B.V, 39–50, 10.1016/j.addr.2016.03.001.
Park, B.J., Choi, H.J., Moon, S.J., Kim, S.J., Bajracharya, R., Min, J.Y., Han, H.K., Pharmaceutical applications of 3D printing technology: current understanding and future perspectives. J. Pharm. Investig. 49:6 (2019), 575–585, 10.1007/s40005-018-00414-y Springer Netherlands.
Parramon-Teixido, C.J., Rodríguez-Pombo, L., Basit, A.W., Worsley, A., Cañete-Ramírez, C., Alvarez-Lorenzo, C., Cabañas-Poy, M.J., Goyanes, A., A framework for conducting clinical trials involving 3D printing of medicines at the point-of-care. Drug Deliv. Transl. Res. 15:9 (2025), 3078–3097, 10.1007/s13346-025-01868-y Springer.
Parulski, C., Bya, L.A., Goebel, J., Servais, A.C., Lechanteur, A., Evrard, B., Development of 3D printed mini-waffle shapes containing hydrocortisone for children's personalized medicine. Int. J. Pharm., 642, 2023, 10.1016/j.ijpharm.2023.123131.
Parulski, C., Evrard, B., Lechanteur, A., Development of new solid oral formulations produced by hot-melt extrusion coupled with fused deposition modeling. 3D printing., 2024, Université de Liège.
Parulski, C., Gresse, E., Jennotte, O., Felten, A., Ziemons, E., Lechanteur, A., Evrard, B., Fused deposition modeling 3D printing of solid oral dosage forms containing amorphous solid dispersions: how to elucidate drug dissolution mechanisms through surface spectral analysis techniques?. Int. J. Pharm., 626, 2022, 10.1016/j.ijpharm.2022.122157.
Parulski, C., Jennotte, O., Lechanteur, A., Evrard, B., Challenges of fused deposition modeling 3D printing in pharmaceutical applications: where are we now?. Adv. Drug Deliv. Rev., 175, 2021, 10.1016/j.addr.2021.05.020 Elsevier B.V.
Patil, R., Bule, P., Chella, N., Exploration of conventional and FDM-mediated 3D printed tablets fabricated using HME-based filaments for pH-dependent drug delivery. AAPS PharmSciTech, 26(4), 2025, 10.1208/s12249-025-03088-6.
Pereira, G.G., Figueiredo, S., Fernandes, A.I., Pinto, J.F., Polymer selection for hot-melt extrusion coupled to fused deposition modelling in pharmaceutics. Pharmaceutics. 12:9 (2020), 1–63, 10.3390/pharmaceutics12090795 MDPI AG.
Ponsar, H., Wiedey, R., Quodbach, J., Hot-melt extrusion process fluctuations and their impact on critical quality attributes of filaments and 3d-printed dosage forms. Pharmaceutics 12:6 (2020), 1–15, 10.3390/pharmaceutics12060511.
Quodbach, J., Bogdahn, M., Breitkreutz, J., Chamberlain, R., Eggenreich, K., Elia, A.G., Gottschalk, N., Gunkel-Grabole, G., Hoffmann, L., Kapote, D., Kipping, T., Klinken, S., Loose, F., Marquetant, T., Windolf, H., Geißler, S., Spitz, T., Quality of FDM 3D printed medicines for pediatrics: considerations for formulation development, filament extrusion, printing process and printer design. Therapeutic Innovation and Regulatory Science. 56:6 (2022), 910–928, 10.1007/s43441-021-00354-0 Springer Science and Business Media Deutschland GmbH.
Rahim, T.N.A.T., Abdullah, A.M., Md Akil, H., Recent developments in fused deposition modeling-based 3D printing of polymers and their composites. Polym. Rev. 59:4 (2019), 589–624, 10.1080/15583724.2019.1597883 Taylor and Francis Inc.
Rowe, R.C., Sheskey, P.J., Quinn, M.E., Handbook of pharmaceutical excipients. (6th ed.)., 2010, The Pharmaceutical Press.
Rowlands, A., Deeb, A., Ladjouze, A., Hamza, R.T., Musa, S.A., Raza, J., Jennane, F., Abu-Libdeh, A., Chanoine, J.P., Access to fludrocortisone and to hydrocortisone in children with congenital adrenal hyperplasia in the WHO eastern mediterranean region: it takes a village. BMJ Glob. Health, 6(10), 2021, 10.1136/bmjgh-2021-007195 BMJ Publishing Group.
Saraf, I., Jakasanovski, O., Stanić, T., Kralj, E., Petek, B., Williams, J.D., Dmytro, N., Georg, G., Bernd, W., Klaus, Z., Perhavec, P., German Ilić, I., Paudel, A., Kushwah, V., Investigation of the influence of copovidone properties and hot-melt extrusion process on level of impurities, in vitro release, and stability of an amorphous solid dispersion product. Mol. Pharm., 2024, 10.1021/acs.molpharmaceut.4c00707.
Shaqour, B., Samaro, A., Verleije, B., Beyers, K., Vervaet, C., Cos, P., Production of drug delivery systems using fused filament fabrication: a systematic review. Pharmaceutics. Vol. 12:6 (2020), 1–16, 10.3390/pharmaceutics12060517 MDPI AG.
Singh, S., Urooj, S., Batra, N., & Kalathil, S. (2020, December 10). Healthcare Applications of 3D Printing in Human Implants: A Review. 2020 IEEE 17th India Council International Conference, INDICON 2020. Doi: 10.1109/INDICON49873.2020.9342316.
Tabriz, A.G., Fullbrook, D.H.G., Vilain, L., Derrar, Y., Nandi, U., Grau, C., Morales, A., Hooper, G., Hiezl, Z., Douroumis, D., Personalised tasted masked chewable 3d printed fruit-chews for paediatric patients. Pharmaceutics, 13(8), 2021, 10.3390/pharmaceutics13081301.
Tan, D.K., Maniruzzaman, M., Nokhodchi, A., Advanced pharmaceutical applications of hot-melt extrusion coupled with fused deposition modelling (FDM) 3D printing for personalised drug delivery. Pharmaceutics, 10(4), 2018, 10.3390/pharmaceutics10040203 MDPI AG.
Thiry, J., Lebrun, P., Vinassa, C., Adam, M., Netchacovitch, L., Ziemons, E., Hubert, P., Krier, F., Evrard, B., Continuous production of itraconazole-based solid dispersions by hot melt extrusion: preformulation, optimization and design space determination. Int. J. Pharm. 515:1–2 (2016), 114–124, 10.1016/j.ijpharm.2016.10.003.
Totaro, M., Racaniello, G.F., Lopalco, A., Lopedota, A.A., Denora, N., Development of 3D-printed captopril mini-tablets with customized release profiles for paediatric hypertension therapy. Int. J. Pharm., 678, 2025, 10.1016/j.ijpharm.2025.125685.
Tracy, T., Wu, L., Liu, X., Cheng, S., Li, X., 3D printing: innovative solutions for patients and pharmaceutical industry. Int. J. Pharm., 631, 2023, 10.1016/j.ijpharm.2022.122480.
United States Pharmacopeia Convention. (2019). USPNF “Fludrocortisone Acetate Tablets.” Doi: 10.31003/USPNF_M33350_05_01.
Vaidya, A., Findling, J., Bancos, I., Adrenal insufficiency in adults: a review. JAMA, 2025, American Medical Association, 10.1001/jama.2025.5485.
Verstraete, G., Samaro, A., Grymonpré, W., Vanhoorne, V., Van Snick, B., Boone, M.N., Hellemans, T., Van Hoorebeke, L., Remon, J.P., Vervaet, C., 3D printing of high drug loaded dosage forms using thermoplastic polyurethanes. Int. J. Pharm. 536:1 (2018), 318–325, 10.1016/j.ijpharm.2017.12.002.
VIDAL. (2025, July 8). Substance active fludrocortisone. Https://Www.Vidal.Fr/Medicaments/Substances/Fludrocortisone-5449.Html#:∼:Text=Par%20voie%20orale%2C%20aux%20doses,Et%20une%20prise%20de%20poids. https://www.vidal.fr/medicaments/substances/fludrocortisone-5449.html#:∼:text=Par%20voie%20orale%2C%20aux%20doses,et%20une%20prise%20de%20poids.
Viidik, L., Vesala, J., Laitinen, R., Korhonen, O., Ketolainen, J., Aruväli, J., Kirsimäe, K., Kogermann, K., Heinämäki, J., Laidmäe, I., Ervasti, T., Preparation and characterization of hot-melt extruded polycaprolactone-based filaments intended for 3D-printing of tablets. Eur. J. Pharm. Sci., 158, 2021, 10.1016/j.ejps.2020.105619.
Wang, Z., Yang, Y., Application of 3D printing in implantable medical devices. Biomed Res. Int., 2021, 2021, 10.1155/2021/6653967 Hindawi Limited.
Windolf, H., Chamberlain, R., Quodbach, J., Predicting drug release from 3D printed oral medicines based on the surface area to volume ratio of tablet geometry. Pharmaceutics, 13(9), 2021, 10.3390/pharmaceutics13091453.
Zhang, J., Feng, X., Patil, H., Tiwari, R.V., Repka, M.A., Coupling 3D printing with hot-melt extrusion to produce controlled-release tablets. Int. J. Pharm. 519:1–2 (2017), 186–197, 10.1016/j.ijpharm.2016.12.049.
Zhang, J., Xu, P., Vo, A.Q., Bandari, S., Yang, F., Durig, T., Repka, M.A., Development and evaluation of pharmaceutical 3D printability for hot melt extruded cellulose-based filaments. J. Drug Delivery Sci. Technol. 52 (2019), 292–302, 10.1016/j.jddst.2019.04.043.
Zhang, J., Yang, W., Vo, A.Q., Feng, X., Ye, X., Kim, D.W., Repka, M.A., Hydroxypropyl methylcellulose-based controlled release dosage by melt extrusion and 3D printing: structure and drug release correlation. Carbohydr. Polym. 177 (2017), 49–57, 10.1016/j.carbpol.2017.08.058.
Zheng, J., Formulation and analytical development for low-dose oral drug products. 2009, John Wiley & Sons.